Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115


Pretransplantation vitamin A plasma levels and risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.

Gjærde LK, Andersen NS, Friis LS, Kornblit B, Petersen SL, Schjødt I, Ostrowski SR, Sengeløv H.

Bone Marrow Transplant. 2019 Nov 26. doi: 10.1038/s41409-019-0760-5. [Epub ahead of print] No abstract available.


Epidemiology of hepatitis E virus infection in a cohort of 4023 immunocompromised patients.

Harritshøj LH, Hother CE, Sengeløv H, Daugaard G, Sørensen SS, Jacobsen S, Perch M, Holm DK, Sækmose SG, Aagaard B, Erikstrup C, Hogema BM, Lundgren JD, Ullum H.

Int J Infect Dis. 2019 Nov 20;91:188-195. doi: 10.1016/j.ijid.2019.11.014. [Epub ahead of print]


Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT.

Heinicke T, Labopin M, Polge E, Niederwieser D, Platzbecker U, Sengelov H, Choi G, Cornelissen J, Blaise D, Kuball J, van Gorkom G, Schaap N, Potter V, Paul F, Savani BN, Nagler A, Mohty M.

Bone Marrow Transplant. 2019 Oct 23. doi: 10.1038/s41409-019-0720-0. [Epub ahead of print]


"Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation".

Wareham NE, Li Q, Sengeløv H, Da Cunha-Bang C, Gustafsson F, Heilmann C, Perch M, Rasmussen A, Sørensen SS, Mocroft A, Lundgren JD.

J Cancer Res Clin Oncol. 2019 Dec;145(12):3125-3135. doi: 10.1007/s00432-019-03039-2. Epub 2019 Nov 5.


Gut microbiome comparability of fresh-frozen versus stabilized-frozen samples from hospitalized patients using 16S rRNA gene and shotgun metagenomic sequencing.

Ilett EE, Jørgensen M, Noguera-Julian M, Daugaard G, Murray DD, Helleberg M, Paredes R, Lundgren J, Sengeløv H, MacPherson C.

Sci Rep. 2019 Sep 16;9(1):13351. doi: 10.1038/s41598-019-49956-7.


Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation.

Minculescu L, Marquart HV, Ryder LP, Andersen NS, Schjoedt I, Friis LS, Kornblit BT, Petersen SL, Haastrup E, Fischer-Nielsen A, Reekie J, Sengelov H.

Front Immunol. 2019 Aug 22;10:1997. doi: 10.3389/fimmu.2019.01997. eCollection 2019.


Development and Validation of a Risk Score for Febrile Neutropenia After Chemotherapy in Patients With Cancer: The FENCE Score.

Aagaard T, Roen A, Reekie J, Daugaard G, Brown PN, Specht L, Sengeløv H, Mocroft A, Lundgren J, Helleberg M.

JNCI Cancer Spectr. 2018 Nov 29;2(4):pky053. doi: 10.1093/jncics/pky053. eCollection 2018 Oct. Erratum in: JNCI Cancer Spectr. 2019 Apr 15;3(1):pkz009.


Incidence Rates and Risk Factors of Clostridioides difficile Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients.

Ilett EE, Helleberg M, Reekie J, Murray DD, Wulff SM, Khurana MP, Mocroft A, Daugaard G, Perch M, Rasmussen A, Sørensen SS, Gustafsson F, Frimodt-Møller N, Sengeløv H, Lundgren J.

Open Forum Infect Dis. 2019 Feb 19;6(4):ofz086. doi: 10.1093/ofid/ofz086. eCollection 2019 Apr.


Reduced Plasma Amino Acid Levels During Allogeneic Hematopoietic Stem Cell Transplantation Are Associated with Systemic Inflammation and Treatment-Related Complications.

Weischendorff S, Kielsen K, Nederby M, Schmidt L, Burrin D, Heilmann C, Ifversen M, Sengeløv H, Mølgaard C, Müller K.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1432-1440. doi: 10.1016/j.bbmt.2019.03.018. Epub 2019 Mar 22.


Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2-6 in patients with solid cancers: The CSR FENCE score.

Aagaard T, Reekie J, Roen A, Daugaard G, Specht L, Sengeløv H, Mocroft A, Lundgren J, Helleberg M.

Int J Cancer. 2020 Jan 15;146(2):321-328. doi: 10.1002/ijc.32249. Epub 2019 Mar 28.


Less mucositis toxicity after 6 versus 3 fractions of high-dose total body irradiation before allogeneic stem cell transplantation.

Sengeløv H, Petersen PM, Fog L, Schmidt M, Specht L.

Bone Marrow Transplant. 2019 Aug;54(8):1369-1371. doi: 10.1038/s41409-019-0470-z. Epub 2019 Feb 4. No abstract available.


Bone marrow mononuclear cell telomere length in acute myeloid leukaemia and high-risk myelodysplastic syndrome.

Warny M, Helby J, Sengeløv H, Nordestgaard BG, Birgens H, Bojesen SE.

Eur J Haematol. 2019 Mar;102(3):218-226. doi: 10.1111/ejh.13196. Epub 2019 Jan 22.


Febrile Neutropenia and Long-term Risk of Infection Among Patients Treated With Chemotherapy for Malignant Diseases.

Nordvig J, Aagaard T, Daugaard G, Brown P, Sengeløv H, Lundgren J, Helleberg M.

Open Forum Infect Dis. 2018 Oct 25;5(10):ofy255. doi: 10.1093/ofid/ofy255. eCollection 2018 Oct.


Mononuclear Cell Telomere Attrition Is Associated with Overall Survival after Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies.

Helby J, Petersen SL, Kornblit B, Nordestgaard BG, Mortensen BK, Bojesen SE, Sengeløv H.

Biol Blood Marrow Transplant. 2019 Mar;25(3):496-504. doi: 10.1016/j.bbmt.2018.09.025. Epub 2018 Sep 26.


Impact of CMV PCR Blips in Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation.

Lodding IP, Mocroft A, da Cunha Bang C, Gustafsson F, Iversen M, Kirkby N, Perch M, Rasmussen A, Sengeløv H, Sørensen SS, Lundgren JD.

Transplant Direct. 2018 May 16;4(6):e355. doi: 10.1097/TXD.0000000000000787. eCollection 2018 Jun.


Classification of death causes after transplantation (CLASS): Evaluation of methodology and initial results.

Wareham NE, Da Cunha-Bang C, Borges ÁH, Ekenberg C, Gerstoft J, Gustafsson F, Hansen D, Heilmann C, Helleberg M, Hillingsø J, Krohn PS, Lodding IP, Lund TK, Lundgren L, Mocroft A, Perch M, Petersen SL, Petruskevicius I, Rasmussen A, Rossing K, Rostved AA, Sengeløv H, Sørensen VR, Sørensen SS, Lundgren JD.

Medicine (Baltimore). 2018 Jul;97(29):e11564. doi: 10.1097/MD.0000000000011564.


Extracorporeal photopheresis is a valuable treatment option in steroid-refractory or steroid-dependent acute graft versus host disease-experience with three different approaches.

Nygaard M, Karlsmark T, Andersen NS, Schjødt IM, Petersen SL, Friis LS, Kornblit BT, Sengeløv H.

Bone Marrow Transplant. 2019 Jan;54(1):150-154. doi: 10.1038/s41409-018-0262-x. Epub 2018 Jun 15. No abstract available.


Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation.

Lodding IP, da Cunha Bang C, Sørensen SS, Gustafsson F, Iversen M, Kirkby N, Perch M, Rasmussen A, Sengeløv H, Mocroft A, Lundgren JD.

Open Forum Infect Dis. 2018 Apr 17;5(5):ofy080. doi: 10.1093/ofid/ofy080. eCollection 2018 May.


The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients.

Wareham NE, Mocroft A, Sengeløv H, Da Cunha-Bang C, Gustafsson F, Heilmann C, Iversen M, Kirkby NS, Rasmussen A, Sørensen SS, Lundgren JD; MATCH in PERSIMUNE study group.

J Cancer Res Clin Oncol. 2018 Aug;144(8):1569-1580. doi: 10.1007/s00432-018-2674-9. Epub 2018 May 26.


Longitudinal follow-up of response status and concomitant immunosuppression in patients treated with extracorporeal photopheresis for chronic graft versus host disease.

Nygaard M, Karlsmark T, Andersen NS, Schjødt IM, Petersen SL, Friis LS, Kornblit BT, Sengeløv H.

Bone Marrow Transplant. 2019 Jan;54(1):35-43. doi: 10.1038/s41409-018-0206-5. Epub 2018 May 8.


Gut decontamination during allogeneic hematopoietic stem cell transplantation and the risk of acute graft-versus-host disease.

Gjærde LK, Schmidt M, Sengeløv H.

Bone Marrow Transplant. 2018 Aug;53(8):1061-1064. doi: 10.1038/s41409-018-0131-7. Epub 2018 Feb 28. No abstract available.


Donor Genotype in the Interleukin-7 Receptor α-Chain Predicts Risk of Graft-versus-Host Disease and Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.

Kielsen K, Enevold C, Heilmann C, Sengeløv H, Pedersen AE, Ryder LP, Müller K.

Front Immunol. 2018 Feb 2;9:109. doi: 10.3389/fimmu.2018.00109. eCollection 2018.


Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival.

Nygaard M, Andersen NS, Moser CE, Olesen G, Schjødt IM, Heilmann C, Sengeløv H.

Bone Marrow Transplant. 2018 Jul;53(7):844-851. doi: 10.1038/s41409-018-0099-3. Epub 2018 Feb 1.


Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study.

Østgård LSG, Lund JL, Nørgaard JM, Nørgaard M, Medeiros BC, Nielsen B, Nielsen OJ, Overgaard UM, Kallenbach M, Marcher CW, Riis AH, Sengeløv H.

Biol Blood Marrow Transplant. 2018 Feb;24(2):314-323. doi: 10.1016/j.bbmt.2017.10.019. Epub 2017 Oct 16.


Risk of infectious diseases among first-degree relatives of transplant recipients who develop CMV infection: is the infectious phenotype inheritable?

Ekenberg C, Lodding IP, Wareham NE, Sørensen SS, Sengeløv H, Gustafsson F, Rasmussen A, Perch M, Lundgren JD, Helleberg M.

Eur J Clin Microbiol Infect Dis. 2017 Dec;36(12):2391-2398. doi: 10.1007/s10096-017-3072-y. Epub 2017 Aug 8.


Epidemiology of bloodstream infections after myeloablative and non-myeloablative allogeneic hematopoietic stem cell transplantation: A single-center cohort study.

Gjaerde LI, Moser C, Sengeløv H.

Transpl Infect Dis. 2017 Oct;19(5). doi: 10.1111/tid.12730. Epub 2017 Jul 12.


Associations between levels of insulin-like growth factor 1 and sinusoidal obstruction syndrome after allogeneic haematopoietic stem cell transplantation.

Weischendorff S, Kielsen K, Sengeløv H, Jordan K, Nielsen CH, Pedersen AE, Ryder LP, Juul A, Müller KG.

Bone Marrow Transplant. 2017 Jun;52(6):863-869. doi: 10.1038/bmt.2017.43. Epub 2017 Apr 24.


Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR).

Gabriel M, Shaw BE, Brazauskas R, Chen M, Margolis DA, Sengelov H, Dahlberg A, Ahmed IA, Delgado D, Lazarus HM, Gibson B, Myers KC, Kamble RT, Abdel-Mageed A, Li CK, Flowers MED, Battiwalla M, Savani BN, Majhail N, Shaw PJ.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1320-1326. doi: 10.1016/j.bbmt.2017.04.004. Epub 2017 Apr 12.


Gastrointestinal Toxicity, Systemic Inflammation, and Liver Biochemistry in Allogeneic Hematopoietic Stem Cell Transplantation.

Jordan K, Pontoppidan P, Uhlving HH, Kielsen K, Burrin DG, Weischendorff S, Christensen IJ, Jørgensen MH, Heilmann C, Sengeløv H, Müller K.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1170-1176. doi: 10.1016/j.bbmt.2017.03.021. Epub 2017 Mar 23.


(GT)n Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation.

Køllgaard T, Kornblit B, Petersen J, Klausen TW, Mortensen BK, Brændstrup P, Sengeløv H, Høgdall E, Müller K, Vindeløv L, Andersen MH, Thor Straten P.

PLoS One. 2016 Dec 20;11(12):e0168210. doi: 10.1371/journal.pone.0168210. eCollection 2016.


The clinical utility of FDG PET/CT among solid organ transplant recipients suspected of malignancy or infection.

Wareham NE, Lundgren JD, Da Cunha-Bang C, Gustafsson F, Iversen M, Johannesen HH, Kjær A, Rasmussen A, Sengeløv H, Sørensen SS, Fischer BM.

Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):421-431. doi: 10.1007/s00259-016-3564-5. Epub 2016 Nov 12.


Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients.

Østgård LS, Nørgaard M, Sengeløv H, Medeiros BC, Kjeldsen L, Overgaard UM, Severinsen MT, Marcher CW, Jensen MK, Nørgaard JM.

Oncotarget. 2016 Nov 1;7(44):72044-72056. doi: 10.18632/oncotarget.12495.


Physical and emotional well-being of survivors of childhood and young adult allo-SCT - A Danish national cohort study.

Jensen JN, Gøtzsche F, Heilmann C, Sengeløv H, Adamsen L, Christensen KB, Larsen HB.

Pediatr Transplant. 2016 Aug;20(5):697-706. doi: 10.1111/petr.12713. Epub 2016 May 27.


Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.

Craddock C, Labopin M, Robin M, Finke J, Chevallier P, Yakoub-Agha I, Bourhis JH, Sengelov H, Blaise D, Luft T, Hallek M, Kröger N, Nagler A, Mohty M.

Haematologica. 2016 Jul;101(7):879-83. doi: 10.3324/haematol.2015.140996. Epub 2016 Apr 14.


Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT.

Cahu X, Labopin M, Giebel S, Aljurf M, Kyrcz-Krzemien S, Socié G, Eder M, Bonifazi F, Bunjes D, Vigouroux S, Michallet M, Stelljes M, Zuckerman T, Finke J, Passweg J, Yakoub-Agha I, Niederwieser D, Sucak G, Sengeløv H, Polge E, Nagler A, Esteve J, Mohty M; Acute Leukemia Working Party of EBMT.

Bone Marrow Transplant. 2016 Mar;51(3):351-7. doi: 10.1038/bmt.2015.278. Epub 2015 Nov 30.


Prognosis of Allogeneic Haematopoietic Stem Cell Recipients Admitted to the Intensive Care Unit: A Retrospective, Single-Centre Study.

Lindgaard SC, Nielsen J, Lindmark A, Sengeløv H.

Acta Haematol. 2016;135(2):72-8. doi: 10.1159/000440937. Epub 2015 Oct 20.


Allogeneic hematopoietic cell transplantation for severe aplastic anemia: similar long-term overall survival after transplantation with related donors compared to unrelated donors.

Mortensen BK, Jacobsen N, Heilmann C, Sengeløv H.

Bone Marrow Transplant. 2016 Feb;51(2):288-90. doi: 10.1038/bmt.2015.231. Epub 2015 Oct 5. No abstract available.


Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.

Granfeldt Østgård LS, Medeiros BC, Sengeløv H, Nørgaard M, Andersen MK, Dufva IH, Friis LS, Kjeldsen E, Marcher CW, Preiss B, Severinsen M, Nørgaard JM.

J Clin Oncol. 2015 Nov 1;33(31):3641-9. doi: 10.1200/JCO.2014.60.0890. Epub 2015 Aug 24.


Clinical Application of Variation in Replication Kinetics During Episodes of Post-transplant Cytomegalovirus Infections.

Lodding IP, Sengeløv H, da Cunha-Bang C, Iversen M, Rasmussen A, Gustafsson F, Downing JG, Grarup J, Kirkby N, Frederiksen CM, Mocroft A, Sørensen SS, Lundgren JD; MATCH Programme Study Group.

EBioMedicine. 2015 May 8;2(7):699-705. doi: 10.1016/j.ebiom.2015.05.003. eCollection 2015 Jul.


Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia.

Ruggeri A, Labopin M, Sanz G, Piemontese S, Arcese W, Bacigalupo A, Blaise D, Bosi A, Huang H, Karakasis D, Koc Y, Michallet M, Picardi A, Sanz J, Santarone S, Sengelov H, Sierra J, Vincent L, Volt F, Nagler A, Gluckman E, Ciceri F, Rocha V, Mohty M; Eurocord, Cord Blood Committee of Cellular Therapy and Immunobiology working party-EBMT; ALWP-EBMT study.

Leukemia. 2015 Sep;29(9):1891-900. doi: 10.1038/leu.2015.98. Epub 2015 Apr 17.


Oral cyclosporine A treatment is feasible after myeloablative conditioning in allogeneic hematopoietic stem cell transplantation.

Nygaard M, Hovgaard D, Schjødt IM, Andersen NS, Vindeløv L, Sengeløv H.

J Clin Pharm Ther. 2015 Jun;40(3):358-61. doi: 10.1111/jcpt.12266. Epub 2015 Mar 31.


Prognostic significance of liver parameters at 1-year follow-up in children and adults undergoing myeloablative allogeneic stem cell transplantation.

Jordan K, Christensen IJ, Jørgensen MH, Heilmann C, Sengeløv H, Müller KG.

Bone Marrow Transplant. 2015 Jun;50(6):876-7. doi: 10.1038/bmt.2015.54. Epub 2015 Mar 23. No abstract available.


The role of gamma delta T cells in haematopoietic stem cell transplantation.

Minculescu L, Sengeløv H.

Scand J Immunol. 2015 Jun;81(6):459-68. doi: 10.1111/sji.12289. Review.


Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis.

Bacigalupo A, Socié G, Hamladji RM, Aljurf M, Maschan A, Kyrcz-Krzemien S, Cybicka A, Sengelov H, Unal A, Beelen D, Locasciulli A, Dufour C, Passweg JR, Oneto R, Signori A, Marsh JC; Aplastic Anemia Working Party of the European Group for Blood Marrow Transplantation.

Haematologica. 2015 May;100(5):696-702. doi: 10.3324/haematol.2014.115345. Epub 2015 Jan 23.


Associations between gastrointestinal toxicity, micro RNA and cytokine production in patients undergoing myeloablative allogeneic stem cell transplantation.

Pontoppidan PL, Jordan K, Carlsen AL, Uhlving HH, Kielsen K, Christensen M, Ifversen M, Nielsen CH, Sangild P, Heegaard NH, Heilmann C, Sengeløv H, Müller K.

Int Immunopharmacol. 2015 Mar;25(1):180-8. doi: 10.1016/j.intimp.2014.12.038. Epub 2015 Jan 20.


Biopsy-verified bronchiolitis obliterans and other noninfectious lung pathologies after allogeneic hematopoietic stem cell transplantation.

Uhlving HH, Andersen CB, Christensen IJ, Gormsen M, Pedersen KD, Buchvald F, Heilmann C, Nielsen KG, Mortensen J, Moser C, Sengeløv H, Müller KG.

Biol Blood Marrow Transplant. 2015 Mar;21(3):531-8. doi: 10.1016/j.bbmt.2014.12.004. Epub 2014 Dec 9.


T cell reconstitution in allogeneic haematopoietic stem cell transplantation: prognostic significance of plasma interleukin-7.

Kielsen K, Jordan KK, Uhlving HH, Pontoppidan PL, Shamim Z, Ifversen M, Heilmann C, Nielsen CH, Sengeløv H, Ryder LP, Müller KG.

Scand J Immunol. 2015 Jan;81(1):72-80. doi: 10.1111/sji.12244.


Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study.

Østgård LS, Nørgaard JM, Sengeløv H, Severinsen M, Friis LS, Marcher CW, Dufva IH, Nørgaard M.

Leukemia. 2015 Mar;29(3):548-55. doi: 10.1038/leu.2014.234. Epub 2014 Aug 5.


Impact of chemotherapy delay on short- and long-term survival in younger and older AML patients: a Danish population-based cohort study.

Ostgard LS, Nørgaard JM, Sengeløv H, Holm MS, Jensen MK, Kallenbach M, Marcher CW, Nielsen OJ, Nørgaard M.

Leukemia. 2014 Sep;28(9):1926-9. doi: 10.1038/leu.2014.157. Epub 2014 May 12. No abstract available.


ProHNPs are specific markers of normal myelopoiesis.

Emmertsen F, Glenthøj A, Sønderskov J, Kampmann P, Sengeløv H, Borregaard N.

Blood Cancer J. 2014 Mar 21;4:e193. doi: 10.1038/bcj.2014.11.

Supplemental Content

Loading ...
Support Center